SYRE vs. ACLX, ADMA, ARWR, MENS, MIRM, MLTX, MTSR, PTGX, AAPG, and LNTH
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs. Its Competitors
Spyre Therapeutics (NASDAQ:SYRE) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Arcellx has higher revenue and earnings than Spyre Therapeutics. Arcellx is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Arcellx had 3 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Arcellx and 6 mentions for Spyre Therapeutics. Arcellx's average media sentiment score of 1.13 beat Spyre Therapeutics' score of 0.77 indicating that Arcellx is being referred to more favorably in the news media.
Spyre Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.
Spyre Therapeutics presently has a consensus target price of $56.17, suggesting a potential upside of 279.25%. Arcellx has a consensus target price of $114.31, suggesting a potential upside of 52.05%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Spyre Therapeutics is more favorable than Arcellx.
80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Arcellx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Spyre Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Arcellx's return on equity of -43.04% beat Spyre Therapeutics' return on equity.
Summary
Arcellx beats Spyre Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 9/16/2025 by MarketBeat.com Staff
Free SYRE Stock Alerts